Iovance Biotherapeutics, Inc. IOVA Non Cash Stock Based Compensation Included In Research And Development
Non Cash Stock Based Compensation Included In Research And Development at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept iova:NonCashStockBasedCompensationIncludedInResearchAndDevelopment.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s non cash stock based compensation included in research and development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s non cash stock based compensation included in research and development?
- Iovance Biotherapeutics, Inc. (IOVA) reported non cash stock based compensation included in research and development of $5.12M in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s non cash stock based compensation included in research and development changed year-over-year?
- Iovance Biotherapeutics, Inc.'s non cash stock based compensation included in research and development decreased by 48.4% year-over-year, from $9.92M to $5.12M.
- What does non cash stock based compensation included in research and development mean?
- This metric captures the non-cash expense related to equity-based compensation for employees and contractors engaged in research and development activities. As a clinical-stage company, this figure highlights the investment in human capital dedicated to pipeline advancement. It is a critical component for evaluating the true economic cost of innovation efforts.